BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 29989234)

  • 1. FDG-PET/CT in the management of lymphomas: current status and future directions.
    El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
    J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma.
    Kobe C; Dietlein M; Hellwig D
    Semin Nucl Med; 2018 Jan; 48(1):28-36. PubMed ID: 29195615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of FDG PET/CT in identification of bone marrow involvement in diffuse large B cell lymphoma and follicular lymphoma: comparison with iliac crest bone marrow biopsy.
    Teagle AR; Barton H; Charles-Edwards E; Dizdarevic S; Chevassut T
    Acta Radiol; 2017 Dec; 58(12):1476-1484. PubMed ID: 28382828
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT: Clinical role in lymphomas.
    Papathanasiou N
    Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
    [No Abstract]   [Full Text] [Related]  

  • 8. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of PET in lymphoma.
    Gallamini A; Borra A
    Curr Treat Options Oncol; 2014 Jun; 15(2):248-61. PubMed ID: 24619427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
    Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Moskowitz CH; Zelenetz A; Schoder H
    J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
    Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
    Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
    [No Abstract]   [Full Text] [Related]  

  • 16. PET/CT in Lymphoma: Current Overview and Future Directions.
    Cheson BD
    Semin Nucl Med; 2018 Jan; 48(1):76-81. PubMed ID: 29195620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
    Karls S; Shah H; Jacene H
    Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18) F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma.
    Ujjani CS; Hill EM; Wang H; Nassif S; Esposito G; Ozdemirli M; Cordova C; Cheson BD
    Br J Haematol; 2016 Aug; 174(3):410-6. PubMed ID: 27098364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET/CT for Staging; Past, Present, and Future.
    El-Galaly TC; Gormsen LC; Hutchings M
    Semin Nucl Med; 2018 Jan; 48(1):4-16. PubMed ID: 29195617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
    Berriolo-Riedinger A; Becker S; Casasnovas O; Vander Borght T; Édeline V
    Cancer Radiother; 2018 Sep; 22(5):393-400. PubMed ID: 30033076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.